
US FDA Rejects Capricor Duchenne Treatment
The US FDA has declined to approve Capricor Therapeutics experimental cell therapy for Duchenne muscular dystrophy. Regulators cited serious data integrity issues and protocol violations in the clinical trial. Following the announcement, Capricor shares slumped significantly in extended trading.
Xurve View
洞察:
Xurve View

The United States Food and Drug Administration declined to approve Capricor Therapeutics Inc's experimental cell therapy, sending shares plunging 77% in extended trading. The rejection on Friday threatens the biotech firm's lead asset and blocks its bid to treat a fatal muscle-wasting condition.







